{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:04:14Z","timestamp":1790654654949,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"DOI":"10.7759\/cureus.96054","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:04:31Z","timestamp":1762243471000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel"],"prefix":"10.7759","author":[{"given":"Mamatha M","family":"Rejeev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavitran","family":"Keechilat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global state of pain treatment. access to medicines and palliative care | HRW. (2011). Accessed:  August 28, 2025: https:\/\/www.hrw.org\/report\/2011\/06\/02\/global-state-pain-treatment\/access-medicines-and-palliative-care."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9185.169088","article-title":"Acute pain services in India: A glimpse of the current scenario","volume":"31","author":"Jain PN","year":"2015","unstructured":"Jain PN, Bakshi SG, Thota RS. Acute pain services in India: A glimpse of the current scenario. J Anaesthesiol Clin Pharmacol. 2015, 31:554-7. 10.4103\/0970-9185.169088","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2016-0064","article-title":"Addressing the barriers related with opioid therapy for management of chronic pain in India","volume":"7","author":"Dureja GP","year":"2017","unstructured":"Dureja GP, Jain PN, Joshi M, Saxena A, Das G, Ahdal J, Narang P. Addressing the barriers related with opioid therapy for management of chronic pain in India. Pain Manag. 2017, 7:311-30. 10.2217\/pmt-2016-0064","journal-title":"Pain Manag"},{"key":"ref4","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin R","year":"2008","unstructured":"Benyamin R, Trescot AM, Datta S, et al.. Opioid complications and side effects. Pain Physician. 2008, 11:S105-20.","journal-title":"Pain Physician"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.7.729","article-title":"The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council","volume":"31","author":"Nikitin D","year":"2025","unstructured":"Nikitin D, Rind DM, McQueen B, et al.. The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2025, 31:729-34. 10.18553\/jmcp.2025.31.7.729","journal-title":"J Manag Care Spec Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00365-7","article-title":"Genetic pain loss disorders","volume":"8","author":"Lischka A","year":"2022","unstructured":"Lischka A, Lassuthova P, \u00c7akar A, et al.. Genetic pain loss disorders. Nat Rev Dis Primers. 2022, 8:41. 10.1038\/s41572-022-00365-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynpai.2024.100168","article-title":"Sodium channels Na(v)1.7, Na(v)1.8 and pain; two distinct mechanisms for Na(v)1.7 null analgesia","volume":"16","author":"Iseppon F","year":"2024","unstructured":"Iseppon F, Kanellopoulos AH, Tian N, et al.. Sodium channels Na(v)1.7, Na(v)1.8 and pain; two distinct mechanisms for Na(v)1.7 null analgesia. Neurobiol Pain. 2024, 16:100168. 10.1016\/j.ynpai.2024.100168","journal-title":"Neurobiol Pain"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2024.102538","article-title":"Drug discovery targeting Na(v)1.8: structural insights and therapeutic potential","volume":"83","author":"Wang H","year":"2024","unstructured":"Wang H, Huang J, Zang J, Jin X, Yan N. Drug discovery targeting Na(v)1.8: structural insights and therapeutic potential. Curr Opin Chem Biol. 2024, 83:102538. 10.1016\/j.cbpa.2024.102538","journal-title":"Curr Opin Chem Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen JD","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, et al.. Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025, 14:655-74. 10.1007\/s40122-024-00697-0","journal-title":"Pain Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-024-01295-7","article-title":"Frontiers in acute pain management: emerging concepts in pain pathways and the role of VX-548 as a novel NaV1.8 inhibitor: a narrative review","volume":"28","author":"Kaye AD","year":"2024","unstructured":"Kaye AD, Everett ES, Lehuquet AM, et al.. Frontiers in acute pain management: emerging concepts in pain pathways and the role of VX-548 as a novel NaV1.8 inhibitor: a narrative review. Curr Pain Headache Rep. 2024, 28:1135-43. 10.1007\/s11916-024-01295-7","journal-title":"Curr Pain Headache Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548","volume":"106","author":"Vaelli P","year":"2024","unstructured":"Vaelli P, Fujita A, Jo S, Zhang HB, Osorno T, Ma X, Bean BP. State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548. Mol Pharmacol. 2024, 106:298-308. 10.1124\/molpharm.124.000944","journal-title":"Mol Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Na(V)1.8 with VX-548 for acute pain","volume":"389","author":"Jones J","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, et al.. Selective inhibition of Na(V)1.8 with VX-548 for acute pain. N Engl J Med. 2023, 389:393-405. 10.1056\/NEJMoa2209870","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"FDA | JOURNAVX (suzetrigine) | Highlights of prescribing information. (2025). Accessed. August 28, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219209s000lbl.pdf."},{"key":"ref15","unstructured":"Evaluation of efficacy and safety of VX-548 for painful diabetic peripheral neuropathy (DPN). (2025). Accessed. 20-10-2025: https:\/\/clinicaltrials.gov\/study\/NCT05660538."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/17581869.2024.2421749","article-title":"VX-548 in the treatment of acute pain","volume":"14","author":"Hang Kong AY","year":"2024","unstructured":"Hang Kong AY, Tan HS, Habib AS. VX-548 in the treatment of acute pain. Pain Manag. 2024, 14:477-86. 10.1080\/17581869.2024.2421749","journal-title":"Pain Manag"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/413614-clinical-efficacy-and-safety-profile-of-suzetrigine-a-novel-non-opioid-analgesic-targeting-nav18-sodium-channel","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:04:37Z","timestamp":1762243477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/413614-clinical-efficacy-and-safety-profile-of-suzetrigine-a-novel-non-opioid-analgesic-targeting-nav18-sodium-channel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.96054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}